NYMX
Income statement / Annual
Last year (2022), Nymox Pharmaceutical Corporation's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, Nymox Pharmaceutical Corporation's net income was -$6.57 M.
See Nymox Pharmaceutical Corporation,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$0.00 |
$0.00 |
$5.00 K |
$116.00 K |
$299.00 K |
$224.00 K |
$283.61 K |
$2.76 M |
$2.95 M |
$3.36 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$4.00 K
|
$58.00 K
|
$138.00 K
|
$149.00 K
|
$173.02 K
|
$160.32 K
|
$173.67 K
|
$486.15 K
|
| Gross Profit |
$0.00
|
$0.00
|
$1.00 K
|
$58.00 K
|
$161.00 K
|
$75.00 K
|
$110.59 K
|
$2.60 M
|
$2.78 M
|
$2.87 M
|
| Gross Profit Ratio |
0
|
0
|
0.2
|
0.5
|
0.54
|
0.33
|
0.39
|
0.94
|
0.94
|
0.86
|
| Research and Development Expenses |
$3.77 M
|
$6.66 M
|
$8.12 M
|
$7.38 M
|
$6.68 M
|
$7.87 M
|
$6.80 M
|
$8.65 M
|
$4.76 M
|
$6.27 M
|
| General & Administrative Expenses |
$2.88 M
|
$5.85 M
|
$3.60 M
|
$6.01 M
|
$4.13 M
|
$5.43 M
|
$6.18 M
|
$11.60 M
|
$2.82 M
|
$1.76 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$8.00 K
|
$6.75 K
|
$9.53 K
|
$186.62 K
|
$282.06 K
|
| Selling, General & Administrative Expenses |
$2.88 M
|
$5.85 M
|
$3.60 M
|
$6.01 M
|
$4.13 M
|
$5.44 M
|
$6.18 M
|
$11.61 M
|
$3.00 M
|
$2.04 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$6.65 M
|
$12.50 M
|
$11.72 M
|
$13.38 M
|
$10.80 M
|
$13.31 M
|
$12.98 M
|
$20.26 M
|
$7.50 M
|
$7.76 M
|
| Cost And Expenses |
$6.65 M
|
$12.50 M
|
$11.73 M
|
$13.44 M
|
$10.94 M
|
$13.46 M
|
$13.15 M
|
$20.42 M
|
$7.67 M
|
$8.24 M
|
| Interest Income |
$1.00 K
|
$8.00 K
|
$27.00 K
|
$213.00 K
|
$72.00 K
|
$11.00 K
|
$3.73 K
|
$0.00
|
$361.00
|
$3.40 K
|
| Interest Expense |
$43.00 K
|
$39.00 K
|
$42.00 K
|
$38.00 K
|
$18.00 K
|
$204.00 K
|
$233.80 K
|
$187.80 K
|
$41.91 K
|
$8.85 K
|
| Depreciation & Amortization |
$363.00 K
|
$262.00 K
|
$294.00 K
|
$778.00 K
|
$3.00 K
|
$1.00 K
|
$3.44 K
|
$6.00 K
|
$6.65 K
|
$9.10 K
|
| EBITDA |
-$6.29 M |
-$12.24 M |
-$11.43 M |
-$12.55 M |
-$10.57 M |
-$13.22 M |
-$12.86 M |
-$17.65 M |
-$4.79 M |
-$4.87 M |
| EBITDA Ratio |
0
|
0
|
-2285.2
|
-108.16
|
-35.34
|
-59.03
|
-45.35
|
-6.39
|
-1.62
|
-1.45
|
| Operating Income Ratio |
0
|
0
|
-2344
|
-114.87
|
-35.59
|
-59.08
|
-45.38
|
-6.4
|
-1.6
|
-1.45
|
| Total Other Income/Expenses Net |
$76.00 K
|
-$33.00 K
|
-$18.00 K
|
$163.00 K
|
$47.00 K
|
-$194.00 K
|
-$240.21 K
|
-$233.56 K
|
$78.61 K
|
-$23.65 K
|
| Income Before Tax |
-$6.58 M
|
-$12.54 M
|
-$11.74 M
|
-$13.16 M
|
-$10.59 M
|
-$13.43 M
|
-$13.11 M
|
-$17.89 M
|
-$4.65 M
|
-$4.91 M
|
| Income Before Tax Ratio |
0
|
0
|
-2347.6
|
-113.47
|
-35.43
|
-59.95
|
-46.22
|
-6.48
|
-1.58
|
-1.46
|
| Income Tax Expense |
-$5.00 K
|
$39.00 K
|
$42.00 K
|
$38.00 K
|
-$47.00 K
|
$0.00
|
$0.00
|
$0.00
|
-$52.00 K
|
$8.85 K
|
| Net Income |
-$6.57 M
|
-$12.58 M
|
-$11.78 M
|
-$13.20 M
|
-$10.59 M
|
-$13.43 M
|
-$13.11 M
|
-$17.89 M
|
-$4.59 M
|
-$4.91 M
|
| Net Income Ratio |
0
|
0
|
-2356
|
-113.79
|
-35.43
|
-59.95
|
-46.22
|
-6.48
|
-1.56
|
-1.46
|
| EPS |
-0.0735 |
-0.15 |
-0.16 |
-0.19 |
-0.18 |
-0.26 |
-0.28 |
-0.48 |
-0.13 |
-0.14 |
| EPS Diluted |
-0.0735 |
-0.15 |
-0.16 |
-0.19 |
-0.18 |
-0.26 |
-0.28 |
-0.48 |
-0.13 |
-0.14 |
| Weighted Average Shares Out |
$89.38 M
|
$81.98 M
|
$73.82 M
|
$68.85 M
|
$60.47 M
|
$52.65 M
|
$46.16 M
|
$37.40 M
|
$35.25 M
|
$34.15 M
|
| Weighted Average Shares Out Diluted |
$89.38 M
|
$81.98 M
|
$73.82 M
|
$68.85 M
|
$60.47 M
|
$52.65 M
|
$46.16 M
|
$37.40 M
|
$35.25 M
|
$34.15 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
